April 1st 2021
The combination of navitoclax and ruxolitinib simultaneously inhibits 2 key mechanisms that promote myelofibrosis, resulting in an improvement in symptom control and positive changes in response biomarkers in patients with high-risk disease.
March 12th 2021
Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.
March 8th 2021
Margetuximab represents an effective new therapeutic option that can be combined safely with a chemotherapy drug of choice for patients with metastatic HER2-positive breast cancer who have undergone multiple lines of prior treatment.
January 20th 2021
Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.
December 5th 2020
ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.
November 4th 2020
An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.
November 4th 2020
The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.
July 15th 2020
Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.
May 31st 2020
The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.
March 6th 2020
The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.